A PYMNTS Company

Takeda Loses Antitrust Appeal Over Patent Listing

By  |  August 25, 2021

Takeda Pharmaceutical must face antitrust litigation over its alleged scheme to delay generic versions of the diabetes drug Actos by exaggerating the scope of its patents to regulators, a federal appeals court in Manhattan ruled Wednesday, August 25.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    The US Court of Appeals for the Second Circuit upheld a decision by Judge Ronnie Abrams, who found that Takeda could be liable for effectively tricking the FDA into requiring other drugmakers to challenge Takeda’s patents instead of letting them “carve out” non-infringing methods of use.

    We’d love to be your preferred source for news.

    Please add us to your preferred sources list so our news, data and interviews show up in your feed. Thanks!

    Add as Preferred Source

    Related:  Takeda Wants 2nd Circuit To Toss Actos Antitrust Suit

    Steven Reed of Morgan, Lewis & Bockius, arguing for Takeda, told the 2nd US Circuit Court of Appeals panel that the Tokyo-based drugmaker had been required by federal law to list two patents that describe combinations of Actos’ active ingredient with other ingredients as pertaining to the drug itself in the Food and Drug Administration’s so-called Orange Book of patents.

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.